Weight 35-25, 12 mg

2 trials

Sponsors

Mazandaran University of Medical Sciences

Conditions

COVID-19 infection. COVID-19, virus identifiedCOVID-19 infection. Coronavirus infection, unspecified

Phase 3

Evaluation of the effect of Ivermectin in treatment of outpatients with COVID-19

RecruitingIRCT20111224008507N4

Mazandaran University of Medical SciencesCOVID-19 infection. Coronavirus infection, unspecified

Start: 2021-02-19Target: 1000Updated: 2021-04-26

Evaluation of the effect of Ivermectin in treatment of patients admitted with COVID-19

RecruitingIRCT20111224008507N5

Mazandaran University of Medical SciencesCOVID-19 infection. COVID-19, virus identified

Start: 2021-02-19Target: 1000Updated: 2021-04-26

Related Papers

Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials

Frontiers in Medicine2022-06-1616 citations